Abstract
Author(s): Amal Muner Mubarak*, Aseel Abdulameer Mohammed, Batool Alkhalidi
Introduction: Hypertensive disorders are a common complication of pregnancy that put women and their fetuses at disproportionate risk for further complications, as well as life-long sequelae. Irisin was reported to have vasodilator, antioxidant, anti-inflammatory effects and to improve endothelial dysfunction, which suggest that it may aid in improvement of placental ischemia during preeclampsia. Aim of the study: To assess level serum irisin in normotensive and preeclamptic pregnancies. Patients and method: A case control study, conducted at the Department of Obstetrics and Gynecology at Al-Zahra?a Teaching Hospital, Al-Najaf city, from the 1st of September 2021 to the first of July 2022. In the current study 60 pregnant women were enrolled, and divided into 2 groups: Thirty pregnant with preeclampsia from 28-40 weeks as case group and other thirty pregnant as healthy uncomplicated normotensive pregnancies as control group. Results: Serum irisin level was (7.28 � 1.3) in patient compared to (9.2 � 1.37) in control group with a (P<0.001). The validity of the test to detect the preeclampsia show that sensitivity was 93%, 54% specificity, negative predictive value was 90.4%, positive predictive value was 56% and accuracy was 70% at 90% CI (0.634 -0.873) with significant association. Conclusions: Serum irisin level was decreased significantly in women with preeclampsia than that in normal pregnancy.